Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the more suitable treatment for the prevention of vascular complications
in diabetes patents who were at high cardiovascular risk group by comparing the platelet
aggregation inhibitory effect of aspirin and cilostazol.